EUVIMEDOpdag EUVIMED
Beobachtungsstudie

Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury

Sushrut S Waikar iD, Robin Mogg iD, Amanda F Baker, Gyorgy Frendl iD, Michael Topper, Scott Adler, Stefan Sultana iD, Runqi Zhao iD, Nicholas M P King iD, Steven P Piccoli iD, John-Michael Sauer iD, Steve Hoffmann and 2 more

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3531 ↗

At a glance

Beobachtungsstudie in Clinical Pharmacology & Therapeutics, 2025. Written by Sushrut S Waikar and 13 co-authors. Institution: Department of Medicine and Section of Nephrology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massa…. Major MEDLINE topics: Acute Kidney Injury. Cited 11 times so far (Crossref); 26 references. Funded by: Food and Drug Administration (FDA), Amgen, Inc., AstraZeneca.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Two observational studies were conducted to support an initiative to qualify translational kidney safety biomarkers as clinical drug development tools that identify tubular injury prior to changes in estimated glomerular filtration rate (eGFR). Normal healthy volunteers provided three morning spot urine collections over 4 weeks. Patients undergoing surgical resection and intrathoracic cisplatin for malignant pleural mesothelioma provided urine samples pre‐ and postoperatively at 4, 8, and 12 hours and daily for 6 days. Using receiver‐operating characteristics curves, “statistically significant thresholds” established peak longitudinal changes for 8 biomarkers to differentiate mesothelioma patients who developed acute kidney injury (AKI) from normal healthy volunteers. We also assessed “medically significant thresholds” to differentiate mesothelioma patients who did vs. did not develop AKI. Statistically and medically significant thresholds for a fold‐change from baseline of urine creatinine (UCr)‐normalized values were established for 6 biomarkers: clusterin (2.2, 5.1); osteopontin (3.1, 7.1); N ‐acetyl‐ ß ‐ D ‐glucosaminidase (2.7, 8.1); kidney injury molecule‐1 (4.3, 7.5); cystatin C (1.8, 4.5); neutrophil gelatinase‐associated lipocalin (2.9, 7.8). For urine albumin and total protein, thresholds were established based on UCr‐normalized absolute values: (> upper limit normal, > 10× upper limit normal). Statistically significant thresholds for all biomarkers outperformed eGFR at discriminating mesothelioma subjects exposed to cisplatin from healthy volunteers, demonstrating their utility for enhancing safe drug development. Medically significant thresholds provide perspective on when patients begin to exhibit AKI. These studies have established guideposts for confirmatory studies with additional cohorts and nephrotoxicants to formally qualify the selected biomarkers with worldwide regulatory authorities.

Subjects

MeSH terms (MEDLINE)

Acute Kidney InjuryAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic AgentsBiomarkersCisplatinCreatinineGlomerular Filtration RateHealthy VolunteersLung NeoplasmsMesotheliomaMesothelioma, Malignant

Substances

Antineoplastic AgentsBiomarkersCisplatinCreatinine

Authors and institutions

  • Department of Medicine and Section of Nephrology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • Critical Path Institute, Tucson, Arizona, USA.
  • Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • AstraZeneca, Cambridge, UK.
  • Neoteric Consulting, Princeton, New Jersey, USA.

ORCID profiles: Sushrut S Waikar, Robin Mogg, Gyorgy Frendl, Stefan Sultana, Runqi Zhao, Nicholas M P King, Steven P Piccoli, John-Michael Sauer, Frank D Sistare

Funding

  • Food and Drug Administration (FDA)
  • Amgen, Inc.
  • AstraZeneca
  • Critical Path Institute's PSTC
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck Sharp & Dohme LLC
  • Merck & Co., Inc.

Cite

APA

Waikar, S. S., Mogg, R., Baker, A. F., Frendl, G., Topper, M., Adler, S., Sultana, S., Zhao, R., King, N. M. P., Piccoli, S. P., Sauer, J. M., Hoffmann, S., Nunes, I., & Sistare, F. D. (2025). Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3531

Vancouver

Waikar SS, Mogg R, Baker AF, Frendl G, Topper M, Adler S, et al. Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3531

BibTeX
@article{Waikar2025,
  author = {Waikar, Sushrut S and Mogg, Robin and Baker, Amanda F and Frendl, Gyorgy and Topper, Michael and Adler, Scott and Sultana, Stefan and Zhao, Runqi and King, Nicholas M P and Piccoli, Steven P and Sauer, John-Michael and Hoffmann, Steve and Nunes, Irene and Sistare, Frank D},
  title = {Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3531}
}
Start for free →